CLIP-qPCR Service for Targeted RBP-RNA Interaction Validation
Do you know the RBP and RNA target but still need to show where the interaction is enriched? Our CLIP-qPCR service combines 254 nm UV crosslinking, immunoprecipitation, and targeted RT-qPCR to test predefined transcripts or regions without running a transcriptome-wide sequencing experiment.
Key Advantages of Our CLIP-qPCR Service:
- Crosslink-Based Capture: UV irradiation stabilizes close RBP-RNA contacts before lysis, allowing stringent washing and more contact-oriented evidence than a native association assay alone.
- Predefined Target Quantification: Focus qPCR capacity on the transcripts and regions central to the hypothesis, so results answer a specific validation question.
- Region-Scanning Design: Compare several predefined amplicons across an RNA to narrow the enriched interval without overclaiming single-nucleotide resolution.
- Control-Aware Interpretation: Input and background controls help distinguish specific enrichment from high RNA abundance or nonspecific recovery.
What Is CLIP-qPCR and When Does It Fit?
CLIP-qPCR combines in-cell UV crosslinking, immunoprecipitation of a selected RNA-binding protein, recovery of crosslinked RNA, reverse transcription, and qPCR detection of predefined RNA targets or regions. It is a targeted validation and localization workflow, not an unbiased discovery assay.
Quick answer: Choose CLIP-qPCR when the RBP and target shortlist are known and you need quantitative, crosslink-based enrichment at selected RNAs or candidate regions. If the targets still need to be identified, discover RBP binding sites with eCLIP-seq before planning targeted confirmation. When the candidate panel is specifically derived from eCLIP discovery, use the peer eCLIP-qPCR service for targeted eCLIP follow-up.
What the assay can establish:
- Whether a selected RNA is enriched in the RBP immunoprecipitate relative to matched controls.
- Whether one predefined region is more enriched than another when several primer pairs cover the same transcript.
- Whether relative enrichment changes across treatments, genotypes, constructs, or cellular states in a matched design.
What it does not establish:
- It does not discover unknown targets across the transcriptome.
- It does not produce sequencing peaks, binding motifs, genome-browser tracks, or pathway enrichment.
- A positive signal supports an in-cell, contact-oriented interaction at the tested region; it does not by itself prove a single causal nucleotide or downstream function.
Input and background controls place target-RBP immunoprecipitation signals in their experimental context.
Build the Target and Primer Plan Around the Biological Question
The value of CLIP-qPCR depends on testing the right transcript version, the right regions, and informative controls. A single amplicon can answer a candidate-enrichment question, while several overlapping or strategically placed amplicons can compare enrichment across a transcript and narrow the interval for follow-up.
Test selected mRNA, lncRNA, circRNA, miRNA, or viral RNA targets. A focused panel directs assay capacity to candidates already supported by discovery data or a mechanistic hypothesis.
Distribute multiple assays across a predefined transcript or domain. Comparing the amplicons helps narrow an enriched interval for subsequent reporter or mutagenesis work.
Align primer placement with the correct transcript accession and splice structure. Version-aware design reduces false interpretation caused by measuring the wrong isoform.
Use the same assays and control logic across treatments, genotypes, constructs, or cellular states so observed differences remain connected to the intended biological variable.
Primer placement is reviewed after RNA fragmentation and transcript context are considered. Shorter recovered fragments can improve regional discrimination, but excessive digestion can reduce recoverable signal. The final design balances localization, RNA recovery, and assay performance.
How CLIP-qPCR Produces Region-Level Enrichment Evidence
The workflow links the biological question to each experimental decision. Candidate regions, comparison groups, antibody suitability, fragmentation, and controls are defined before qPCR so the final values can support a clear confirm, deprioritize, or redesign decision.
The workflow connects target design, 254 nm UV crosslinking, controlled capture, and transparent region-level reporting.
- Project and Target Design: We review the RBP, sample, antibody, transcript identifiers, candidate regions, comparison groups, and controls. Early checks prevent avoidable transcript-version and assay-design errors.
- Sample Preparation and 254 nm UV Crosslinking: UV exposure creates covalent bonds at close RBP-RNA contacts before lysis. This supports stringent downstream washing and makes the recovered signal more informative for contact-oriented validation.
- Lysis and Controlled RNA Fragmentation: RNA is partially fragmented while immunoprecipitable RBP-RNA complexes are preserved. Controlled fragmentation improves regional discrimination without sacrificing unnecessary signal.
- RBP Immunoprecipitation with Matched Controls: The target antibody enriches the selected RBP complex, while input and background controls measure RNA abundance and nonspecific recovery. This keeps a low Cq value from being mistaken for specific binding when the transcript is simply abundant.
- Protein Digestion, RNA Recovery, and Reverse Transcription: Protein is removed, RNA is purified, and recovered RNA is converted to cDNA. Consistent handling across IP and control arms protects comparability.
- Targeted qPCR and Reporting: Prequalified assays measure selected RNA targets or regions. Normalized results remain linked to raw Cq values, replicates, and controls so candidate rankings can be reviewed.
The standard description uses 254 nm UVC without required photoactivatable nucleoside incorporation. A workflow that incubates cells with 4-thiouridine and uses 365 nm UVA is PAR-CLIP and should be planned and labeled separately.
Plan Your Target PanelSample, Antibody, and Control Requirements
Starting material and antibody performance determine whether the assay can generate interpretable enrichment. The recommendations below preserve material for immunoprecipitation and matched controls, reducing the risk that low signal reflects insufficient input rather than biology.
| Sample or Item | Recommended Input | Quality or Preparation | Why It Matters |
|---|---|---|---|
| Cultured Cells | ≥ 1 × 10^8 cells | Viability ≥ 90%; fresh material preferred | High viability limits released-RNA background, while the recommended biomass supports IP and control arms. |
| Animal Tissue | ≥ 500 mg | Snap-frozen promptly after collection | Adequate starting mass leaves material for extraction, controls, and planned comparisons. |
| Plant Tissue | ≥ 5 g | Snap-frozen; avoid repeated freeze-thaw cycles | The higher input accommodates disruption and extraction losses from cell-wall-rich material. |
| RBP Antibody | 10-15 µg per assay | IP- or RIP-validated antibody preferred; provide datasheet and prior WB/IP evidence | Prior immunocapture evidence reduces the chance that weak enrichment is caused by antibody performance. |
| Candidate Targets | Transcript ID, candidate region, sequence or coordinates | Provide reference assembly and transcript version | Version-matched information prevents isoform or coordinate mismatches during assay design. |
| Study Groups | Clearly labeled biological groups and controls | Process comparison groups in a matched design | Matched handling makes enrichment differences easier to attribute to the biological variable. |
Input provides starting-abundance context, while IgG or another planned background control estimates nonspecific recovery. Positive and negative RNA regions, no-UV arms, or genetic controls can be added when they answer a defined experimental risk. Other sample types and final inputs are reviewed before collection; low-abundance RBPs, limited specimens, or antibodies without prior IP evidence may require a pilot.
Quantitative Analysis Without Sequencing Bioinformatics
CLIP-qPCR uses targeted qPCR analysis rather than a sequencing bioinformatics pipeline. Raw Cq values, assay quality, input-aware normalization, background comparison, replicate consistency, and target or region ranking remain visible so each reported result can be audited.
- Raw Cq Review: IP, input, and background-control values are retained, preserving the measurement layer behind each normalized result.
- Assay Quality Review: Amplification behavior and planned specificity criteria are checked before enrichment values are interpreted.
- Input-Aware Normalization: Input measurements account for starting transcript abundance, helping separate true IP enrichment from a transcript that is abundant in every fraction.
- Background Comparison: IgG or another planned negative control estimates nonspecific recovery, so the IP signal is not interpreted in isolation.
- Replicate and Region Summaries: Replicate-level values remain visible alongside group summaries, region rankings, and condition comparisons.
No universal enrichment cutoff is imposed across all RBPs and sample types. Interpretation considers antibody performance, control behavior, assay quality, target abundance, replicate pattern, and the biological question together.
Results and Deliverables You Can Trace Back to the Experiment
The result package preserves both the measurement and interpretation layers. Your team can inspect underlying qPCR values, compare targets and regions, and use the summarized plots to plan subsequent perturbation or mechanism experiments.
Representative result formats connect raw qPCR measurements with target-, region-, and condition-level interpretation. The illustration contains no project-derived numeric data.
Standard Deliverables:
- Project design summary with samples, RBP, antibody, target regions, and controls.
- Primer/amplicon map for tested candidate regions.
- Raw Cq table and qPCR QC summary.
- Input- and background-normalized enrichment results.
- Replicate-level and group-level comparison tables.
- Candidate-focused interpretation and final project report.
Representative Result Views:
- Target Enrichment Plot: Identifies selected RNAs that merit downstream work.
- Region-Scanning Plot: Aligns qPCR amplicons to a transcript and narrows a predefined candidate interval.
- Condition Comparison Plot: Shows whether relative enrichment changes across treatments, genotypes, or constructs.
- Cq and Normalization Summary: Connects raw measurements with reported values for transparent review.
Applications of Targeted CLIP-qPCR
The service is most useful after the RBP and candidate list are defined. It converts discovery signals or mechanistic hypotheses into focused quantitative evidence that can guide the next experiment.
Confirm selected transcripts or candidate regions from eCLIP-seq or another discovery dataset. Targeted follow-up can separate priority interactions from candidates that do not reproduce under qPCR controls.
Compare multiple amplicons across an mRNA, lncRNA, circRNA, miRNA, or viral RNA and narrow the enriched interval for subsequent mechanistic work.
Test whether the same RBP-RNA interaction changes after treatment, perturbation, stress, differentiation, or genotype change using matched target assays.
Rank regions before splicing, stability, localization, translation, reporter, or mutagenesis experiments. Projects that first need transcript candidates may instead identify RBP-associated transcripts with RIP-seq.
Research areas supported:
Beyond these workflow-stage uses, CLIP-qPCR can test defined RBP-RNA hypotheses across a range of biological fields. Cell lines, primary cells, organoids, animal-model-derived material, and plant samples can be considered, but antibody performance, UV access, sample composition, and primer feasibility should be reviewed for each model.
Test whether RNA-modification writers, readers, or erasers bind predefined transcripts or regions, including candidate m6A-regulated RNAs. CLIP-qPCR measures RBP-RNA enrichment rather than modification abundance, so it can be paired with targeted RNA methylation enrichment by MeRIP-qPCR when both occupancy and modification status matter.
Study RBP control of oncogenic transcripts, tumor-suppressor RNAs, noncoding RNAs, and treatment-response candidates in human cancer cells, organoids, or mouse-model-derived material. Defined region assays help prioritize interactions for stability, splicing, translation, or drug-response experiments.
Examine RBP interactions involved in neuronal differentiation, alternative splicing, RNA transport, local translation, synaptic function, or neurodegeneration using neuronal, retinal, or brain-derived systems from human or rodent models.
Evaluate selected RBP-RNA interactions in liver-, adipose-, pancreatic-, vascular-, or cardiac-derived models under nutrient change, hypoxia, lipid stress, or metabolic perturbation. Matched assays can show whether the candidate interaction changes with the biological condition.
Test RBP binding to cytokine, signaling, and immune-cell-state transcripts during macrophage polarization, lymphocyte activation, inflammatory stimulation, or immune-gene perturbation. Targeted quantification helps select interactions for downstream functional assays.
Assess whether a host RBP or pathogen-encoded protein enriches selected viral or host RNAs in infected and control systems. Regional assays can focus hypotheses involving viral RNA stability, translation, replication, packaging, or innate immune sensing.
Compare defined RBP-RNA interactions during stem-cell maintenance, lineage commitment, embryoid-body formation, or organ development. This helps connect changes in RNA binding with candidate splicing, localization, stability, or translation programs.
Investigate selected plant RBP targets in circadian regulation, flowering, hormone response, cold, drought, or other stress programs in Arabidopsis, rice, maize, and additional species. Cell-wall disruption, pigments, crosslinking, and antibody suitability require model-specific feasibility review.
Case Study: CLIP-qPCR Narrows TIAR Binding on HBV pgRNA
This external literature example shows how serial qPCR-region testing can move from a full RNA molecule to a smaller candidate interaction interval.
Choose CLIP-qPCR, eCLIP-qPCR, RIP-qPCR, eCLIP-seq, or PAR-CLIP-seq
Method choice should follow the question that needs to be answered. CLIP-qPCR is a focused validation option when the RBP and target regions are known; it is not a substitute for an unbiased binding map.
| Method | Primary Question | Predefined Targets? | Readout | Best Use |
|---|---|---|---|---|
| CLIP-qPCR | Does a defined RBP enrich selected RNA targets or regions after UV crosslinking? | Required | Targeted RT-qPCR | Focused validation, region scanning, and condition comparison |
| eCLIP-qPCR | Are selected eCLIP-informed RBP-RNA candidates enriched under targeted controls? | Required | Targeted RT-qPCR | Focused follow-up when the shortlist is specifically prioritized from eCLIP discovery |
| RIP-qPCR | Is a selected RNA associated with an immunoprecipitated RNP complex? | Required | Targeted RT-qPCR | Targeted RNP association testing with RIP-qPCR when crosslink-oriented contact evidence is not central |
| eCLIP-seq | Where does the RBP bind across the transcriptome? | Not required | High-throughput sequencing | Unbiased target discovery and global binding maps |
| PAR-CLIP-seq | Where are photoactivatable-nucleoside-supported contacts across the transcriptome? | Not required | High-throughput sequencing | Photoactivatable crosslinking with PAR-CLIP-seq when the design specifically calls for 4SU/6SG incorporation and 365 nm UVA |
Best for: Projects with a defined RBP, a suitable antibody, and predefined RNA targets or regions that need crosslink-based quantitative validation.
Not for: Unbiased target discovery, transcriptome-wide peak or motif analysis, or experiments expecting qPCR alone to identify one causal nucleotide. The 4SU plus 365 nm workflow belongs to PAR-CLIP, not the standard 254 nm CLIP-qPCR workflow presented here.
Frequently Asked Questions
References
- Yoon, J. H., and M. Gorospe. "Cross-Linking Immunoprecipitation and qPCR (CLIP-qPCR) analysis to map interactions between long noncoding RNAs and RNA-binding proteins." Methods in Molecular Biology, vol. 1402, 2016, pp. 11-17.
- Ule, J., et al. "CLIP: A method for identifying protein-RNA interaction sites in living cells." Methods, vol. 37, no. 4, 2005, pp. 376-386.
- Lee, F. C. Y., and J. Ule. "Advances in CLIP Technologies for Studies of Protein-RNA Interactions." Molecular Cell, vol. 69, no. 3, 2018, pp. 354-369.
- Ule, J., H. W. Hwang, and R. B. Darnell. "The Future of Cross-Linking and Immunoprecipitation (CLIP)." Cold Spring Harbor Perspectives in Biology, vol. 10, no. 8, 2018, article a032243.
- Bustin, S. A., et al. "The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments." Clinical Chemistry, vol. 55, no. 4, 2009, pp. 611-622.
- Zhang, T., et al. "RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation." Signal Transduction and Targeted Therapy, vol. 8, 2023, article 346.
Disclaimer: For Research Use Only. This service is not intended for diagnostic procedures, patient management, or treatment decisions. Project feasibility, control design, and assay scope are finalized according to the submitted samples, antibody, targets, and research objective.